In 2024, Halozyme Therapeutics completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Halozyme Therapeutics has also provided a category-level breakdown for 1 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 |
|---|---|
Total Scope 1 | 1,347.71a |
Total Scope 2 | |
Location-Based | 2,113.45a |
Total Scope 3 | 30.46a |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 1.3274a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2024, the total operational greenhouse gas (GHG) emissions of Halozyme Therapeutics amounted to 3,461.16 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
In 2024, the total Scope 1 emissions of Halozyme Therapeutics were 1,347.71 metric tons of CO₂ equivalent (tCO₂e).a
In 2024, Halozyme Therapeutics reported Scope 2 greenhouse gas (GHG) emissions of 2,113.45 tCO₂e using the location-based method.a
In 2024, Halozyme Therapeutics reported its Scope 2 emissions using the location-based method.a
In 2024, Halozyme Therapeutics reported 30.46 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2024 disclosure of Halozyme Therapeutics includes a breakdown across 1 of the 15 Scope 3 categories defined by the GHG Protocol, up from 0 in , reflecting improved emissions accounting practices and greater transparency across the company's value chaina
In 2024, Halozyme Therapeutics reported total Scope 3 emissions of 30.46 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 100% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0% came from downstream activities like product use, distribution, and end-of-life treatment.a
In 2024, Halozyme Therapeutics reported emissions for 1 out of the 15 Scope 3 categories defined by the GHG Protocol.a
The limited disclosure restricts visibility into specific emission sources across the company's value chain.
In 2024, the largest contributors to Halozyme Therapeutics's Scope 3 emissions were:a
In 2024, Halozyme Therapeutics reported Scope 1 greenhouse gas (GHG) emissions of 1,347.71 tCO₂e and total revenues of USD 1,015 millions. This translates into an emissions intensity of 1.33 tCO₂e per millions USD.a
In 2024, Halozyme Therapeutics reported a Scope 1 emissions intensity of 1.33 tCO₂e per millions USD. Compared to the peer group median of 4.58, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
In 2024, Halozyme Therapeutics ranked 5 out of 21 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
This places Halozyme Therapeutics among the top performers, with one of the lowest emissions intensities relative to peers.a
In 2024, Halozyme Therapeutics reported a total carbon footprint of 3,491.62 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions.a
The largest contributor to Halozyme Therapeutics's total carbon footprint was Scope 2 emissions, accounting for 60.53% of the company's total carbon footprint, followed by Scope 1 emissions at 38.6%.a